Citation: | CAO Gao-xiang, LI Yi-jie, SHI Yi, SONG Guo-lei, JIANG Cong-qiao. Expression of TACC3 and its relationship with epithelial mesenchymal transformation in gastric adenocarcinoma[J]. Chinese Journal of General Practice, 2022, 20(5): 740-744. doi: 10.16766/j.cnki.issn.1674-4152.002443 |
[1] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
|
[2] |
VENERITO M, LINK A, ROKKAS T, et al. Review: Gastric cancer-clinical aspects[J]. Helicobacter, 2019, 24: e12643. DOI: 10.1111/hel.12643.
|
[3] |
STRONG V E. Progress in gastric cancer[J]. Updates Surg, 2018, 70(2): 157-159. doi: 10.1007/s13304-018-0543-3
|
[4] |
张英杰, 梁金荣. 腹腔镜胃癌根治术治疗进展期胃癌患者的近期疗效及对腹腔内微转移的影响[J]. 中华全科医学, 2017, 15(11): 1867-1869, 1890. doi: 10.16766/j.cnki.issn.1674-4152.2017.11.013
ZHANG Y J, LIANG Y R. Short-term efficacy of laparoscopic radical gastrectomy for advanced gastric cancer and its influence on intra-abdominal micrometastases[J]. Chinese general practice, 2017, 15(11): 1867-1869, 1890. doi: 10.16766/j.cnki.issn.1674-4152.2017.11.013
|
[5] |
COSTA R, CARNEIRO B A, TAXTER T, et al. FGFR3-TACC3 fusion in solid tumors: Mini review[J]. Oncotarget, 2016, 7(34): 55924-55938. doi: 10.18632/oncotarget.10482
|
[6] |
FRATTINI V, PAGNOTTA S M, TALA, et al. A metabolic function of FGFR3-TACC3 gene fusions in cancer[J]. Nature, 2018, 553(7687): 222-227. doi: 10.1038/nature25171
|
[7] |
LIN Z R, WANG M Y, HE S Y, et al. TACC3 transcriptionally upregulates E2F1 to promote cell growth and confer sensitivity to cisplatin in bladder cancer[J]. Cell Death Dis, 2018, 9(2): 72. doi: 10.1038/s41419-017-0112-6
|
[8] |
DING Z M, HUANG C J, JIAO X F, et al. The role of TACC3 in mitotic spindle organization[J]. Cytoskeleton(Hoboken), 2017, 74(10): 369-378.
|
[9] |
CAMPO L, BREUER E K. Inhibition of TACC3 by a small molecule inhibitor in breast cancer[J]. Biochemi Biophys Res Commun, 2018, 498(4): 1085-1092. doi: 10.1016/j.bbrc.2018.03.125
|
[10] |
MA W J, GU Y K, PENG J H, et al. Pretreatment TACC3 expression in locally advanced rectal cancer decreases the response to neoadjuvant chemoradiotherapy[J]. Aging, 2018, 10(10): 2755-2771. doi: 10.18632/aging.101585
|
[11] |
WANG Y, DING X, HU H, et al. Long non-coding RNA lnc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3[J]. Int J Cancer, 2018, 143(12): 3143-3154. doi: 10.1002/ijc.31657
|
[12] |
石斌, 樊平, 许方方. 白细胞介素1β对结直肠癌细胞HCT116迁移能力和上皮-间质转化的影响[J]. 安徽医学, 2019, 40(10): 1079-1083. doi: 10.3969/j.issn.1000-0399.2019.10.001
SHI B, FAN P, XU F F. Effects of interleukin-1β on the migration ability and epithelial-mesenchymal transition of colorectal cancer cells HCT116[J]. Anhui Medical Journal, 2019, 40(10): 1079-1083. doi: 10.3969/j.issn.1000-0399.2019.10.001
|
[13] |
XIA P, XU X Y. Epithelial-mesenchymal transition and gastric cancer stem cell[J]. Tumour Biol, 2017. DOI: 10.1177/1010428317698373.
|
[14] |
DONGRE A, WEINBERG R A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer[J]. Nat Rev Mol Cell Biol, 2019, 20(2): 69-84.
|
[15] |
LU W, KANG Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis[J]. Dev Cell, 2019, 49(3): 361-374. doi: 10.1016/j.devcel.2019.04.010
|
[16] |
ALLEMANI C, MATSUDA T, DI CARLO V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. doi: 10.1016/S0140-6736(17)33326-3
|
[17] |
王珣, 张鹏, 刘智明, 等. MiR-22靶向调控CD151促进胃癌血管新生的机制研究[J]. 中华全科医学, 2018, 16(12): 1984-1988. doi: 10.16766/j.cnki.issn.1674-4152.000541
WANG X, ZHANG P, LIU Z M, et al. Study on the mechanism of MiR-22 targeting CD151 to promote angiogenesis in gastric cancer[J]. Chinese general practice, 2018, 16(12): 1984-1988. doi: 10.16766/j.cnki.issn.1674-4152.000541
|
[18] |
AKBULUT O, LENGERLI D, SAATCI O, et al. A highly potent TACC3 inhibitor as a novel anticancer drug candidate[J]. Mol Cancer Ther, 2020, 19(6): 1243-1254. doi: 10.1158/1535-7163.MCT-19-0957
|
[19] |
LASORELLA A, SANSON M, IAVARONE A. FGFR-TACC gene fusions in human glioma[J]. Neuro Oncol, 2017, 19(4): 475-483.
|
[20] |
JOHNSTON K J, WEN H, HOCKENBERRY J M, et al. Association between patient cognitive and functional status and medicare total annual cost of care: Implications for value-based payment[J]. JAMA Intern Med, 2018, 178(11): 1489-1497. doi: 10.1001/jamainternmed.2018.4143
|
[21] |
DHAMI J, HIRSHFIELD K M, GANESAN S, et al. Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer[J]. Cold Spring Harb Mol Case Stud, 2018, 4(2). DOI: 10.1101/mcs.a002089.
|
[22] |
MATSUDA K, MIYOSHI H, HIRAOKA K, et al. Elevated expression of transforming acidic coiled-coil containing protein 3 (TACC3) is associated with a poor prognosis in osteosarcoma[J]. Clin Orthop Relat Res, 2018, 476(9): 1848-1855. doi: 10.1097/CORR.0000000000000379
|
[23] |
张益玮, 彭秀达, 肖帅. 上皮-间充质转变的概念变迁及与肿瘤转移研究进展[J]. 中国普通外科杂志, 2020, 29(2): 241-247. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202002020.htm
ZHANG Y W, PENG X D, XIAO S. Conceptual changes of epithelial-mesenchymal transition and research progress on tumor metastasis[J]. Chinese Journal of General Surgery, 2020, 29(2): 241-247. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202002020.htm
|
[24] |
PAKULA M, PIETRASIK M J, WITUCKA A, et al. The epithelial-mesenchymal transition initiated by malignant ascites underlies the transmesothelial invasion of ovarian cancer cells[J]. Int J Mol Sci, 2019, 20(1): 137. doi: 10.3390/ijms20010137
|